Here are a whole slew of distinguished institutions, regulatory and government agencies recognizing DCVax-L, contradicting your "opinion".
This seems like quite a distinguished group of institutions associated with the treatment and trial, not "shunning" it:
1Department of Neurosurgery, University of California, Los Angeles 2King’s College Hospital, London, United Kingdom 3Department of Neurosurgery, Penn Brain Tumor Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia 4Division of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri 5Givens Brain Tumor Center, Abbott Northwestern Hospital, Minneapolis, Minnesota 6Columbia University Irving Medical Center, New York, New York 7New York-Presbyterian Hospital, New York, New York 8Preston A. Wells, Jr. Center for Brain Tumor Therapy, Division of Neuro-Oncology, Lillian S. Wells Department of Neurosurgery, University of Florida College of Medicine, Gainesville 9Department of Neurological Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri 10Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Medical Center, Seattle, Washington 11Taubman Medical Center, University of Michigan, Ann Arbor 12Neuro-Oncology Program, Rutgers Cancer Institute of New Jersey, New Brunswick 13Sutter Health, Sacramento, California 14Glasser Brain Tumor Center, Atlantic Healthcare, Summit, New Jersey 15Department of Neurological Sciences, Rush Medical College, Chicago, Illinois 16Department of Neurology, The Ohio State University, Columbus 17The Cancer Center of Columbus Regional Health, Columbus, Indiana 18University of Rochester, Rochester, New York 19University of Cincinnati, Cincinnati, Ohio 20John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey 21Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan 22Department of Neurology and Chao Family Comprehensive Cancer Center, University of California, Irvine 23Rhode Island Hospital, Providence 24Long Island Brain Tumor Center at NSPC, Lake Success, New York 25Department of Neurosurgery, University of Colorado Health Sciences Center, Boulder 26Ascension St Thomas Brain and Spine Tumor Center, Howell Allen Clinic, Nashville, Tennessee 27Mays Cancer Center at UT Health San Antonio, San Antonio, Texas 28Department of Neurosurgery, UNC School of Medicine and UNC Health, Chapel Hill, North Carolina 29The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 30Advent Health, Kansas City, Kansas 31Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California 32Division of Neuro-Oncology, Icahn School of Medicine at Mount Sinai, New York, New York 33Saint Joseph’s Hospital, Orange, California 34Jefferson Hospital for Neurosciences, Jefferson University, Philadelphia, Pennsylvania 35Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 36Beth Israel Deaconess Medical Center, Harvard Medical School, Cambridge, Massachusetts 37Baylor Scott & White Neuro-Oncology Associates, Dallas, Texas 38Illinois Cancer Care, Galesburg, Peoria 39Medical University of South Carolina Neurosciences, Charleston 40Mount Sinai Medical Center, Miami Beach, Florida 41Uniklinikum Dresden, Dresden, Germany 42Hollings Cancer Center, Medical University of South Carolina, Charleston 43Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida 44BG Klinikum Bergmannstrost, Halle, Germany 45Neurochirurgie Katharinenhospital, Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany 46Seidman Cancer Center, University Hospitals–Cleveland Medical Center, Cleveland, Ohio 47Department of Neurosurgery, Tufts Medical Center, Boston, Massachusetts 48Piedmont Physicians Neuro-Oncology, Piedmont Brain Tumor Center, Atlanta, Georgia 49Department of Neuro-Oncology, Moffitt Cancer Center 50Pacific Neurosciences Institute and Saint John’s Cancer Institute, Santa Monica, California 51Centre de Recherche du CHUS, Université de Sherbrooke, Sherbrooke, Quebec, Canada 52UC San Diego Moore’s Cancer Center, La Jolla, California 53Department of Neurosurgery, Houston Methodist Hospital, Houston, Texas 54Geisinger Neuroscience Institute, Danville, Pennsylvania 55Klinik für Neurochirurgie, Chemnitz, Germany 56Baptist Health System, San Antonio, Texas 57Saint Luke’s Cancer Institute, Kansas City, Missouri 58Departments of Neurosurgery and Medicine, The Warren Alpert Medical School of Brown University, Providence, Rhode Island 59Kaiser Permanente, Redwood City, California 60University of Kentucky Markey Cancer Center, Department of Medicine, Neurosurgery, and Neurology, University of Kentucky, Lexington 61Oklahoma University Health Science Center, Oklahoma City 62University College London Hospitals, London, United Kingdom 63Blue Sky Neurology/Neuro-Oncology, Englewood, California 64Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada 65Department of Neurosurgery, Zucker School of Medicine at Hofstra/Northwell, Uniondale, New York 66University of California, Los Angeles 67Northwest Biotherapeutics, Inc, Bethesda, Maryland
The UCLA Health Brain Tumor Center is a designated Specialized Program of Research Excellence (SPORE) site funded by the National Cancer Institute. The UCLA SPORE in Brain Cancer contributes significantly to progress in the diagnosis, prognosis and treatment of brain cancer, and these goals are accomplished through diverse research projects involving mechanistic pre-clinical work and innovative clinical studies. The SPORE includes research for several brain cancer types, including low- and high-grade glioma, glioblastoma, and meningioma.
NW Bio's DCVax-L is the first immune therapy to be granted a Hospital Exemption approval under the German Drug Law. The scope of this Hospital Exemption includes all glioma brain cancers, both GBM (the most severe grade) and lower grade (less malignant) gliomas, and includes both newly diagnosed (i.e., early stage) as well as recurrent (i.e., late stage) patients. The patients must receive treatment in Germany, but may be either from Germany or from abroad.
And UCLA seems proud of it:
FDA approvals may move UCLA brain cancer and Alzheimer’s treatments from bench to bedside Glioblastoma and Alzheimer’s disease treatments advance through clinical trials. - June 12, 2023
...
A vaccine to treat glioblastoma
Glioblastoma is the most aggressive primary brain tumor in adults, with more than 10,000 new cases diagnosed in the United States each year. Standard treatment involves surgery, radiation, and chemotherapy; and the median overall survival rate is only 15 to 17 months from diagnosis.
A vaccine to treat glioblastoma called DCVax-L has been in development for several years. Linda Liau, MD, PhD, MBA, and a team of UCLA researchers were the first to investigate whether a patient’s own dendritic cells (a specialized type of immune cell) could be used to create a personalized treatment for the deadly cancer.
“We tested the method with a single patient in 1997, and then moved to a phase 1 safety trial in the early 2000s,” says Dr. Liau, professor and chair of Neurosurgery at UCLA.
A series of phase 2 early efficacy and optimization trials followed, and then an international, multi-site study led by Dr. Liau began in 2007.
The vaccine consists of two components: a patient’s dendritic cells, which are special types of immune cells, and proteins prepared from a patient’s tumor.
To create the vaccine, which is individualized for each patient, medical staff first perform a procedure called leukapheresis, in which a patient’s blood is drawn and their white blood cells are collected. Then, the patient’s tumor is removed and sent to a lab where researchers obtain proteins from the specimen, called tumor lysate. The white blood cells are cultured to differentiate into dendritic cells, and then combined with the tumor lysate to make the vaccine.
Dendritic cells are “antigen-presenting” cells, which means that they are able to process all kinds of foreign invaders in the body and alert the immune system’s T cells to mobilize a broad immune response against those invaders. Glioblastoma is a highly heterogenous disease, meaning there are many different types of cancer cells within a single tumor. Therefore, the dendritic cells — loaded with a patient’s own tumor lysate — allow a patient’s immune system to recognize a wide variety of tumor targets and spur the immune system to respond, according to Dr. Liau.
The phase 3 trial led by Dr. Liau involved 331 study participants at 80 sites around the world from August 2007 to November 2015. During the study, 232 people received standard care and DCVax-L at new diagnosis, while 64 out of 99 people received standard care and a placebo. (Patients in the placebo group received the DCVax-L at recurrence.)
The trial results, published in JAMA Oncology in November 2022, showed that newly diagnosed glioblastoma patients receiving the vaccine had an overall survival of 19.3 months on average, compared to 16.5 months on average among the contemporaneous, matched external control group.
“There is a significant subgroup of patients who lived more than five years, but the challenge is trying to determine which patients it may work for, and for which patients it doesn’t,” Dr. Liau says.
At UCLA, Dr. Liau and other researchers are now testing whether the vaccine would be more effective in combination with a PD-1 checkpoint inhibitor. Checkpoint inhibitors are a type of immunotherapy that work by blocking proteins that stop the immune system from attacking cancer cells. While the vaccine allows T-cells to get inside of the tumor, the checkpoint inhibitors may allow T-cells to be more functional and better attack the tumor cells.
“Because of the heterogeneity of glioblastoma, I don’t think there is going to be one drug or one treatment that is going to be effective for all patients. The future of glioblastoma treatments is going to be these combination approaches,” Dr. Liau says.
Researchers Announce Breakthrough in Brain Cancer Vaccine Trial
“PROVIDENCE, R.I. (WPRI) — Lifespan researchers say they have made a major breakthrough in fighting brain cancer.
The Lifespan Cancer Institute held a news conference at Rhode Island Hospital to present results from a vaccine trial for glioblastoma, the most common and lethal form of brain cancer.
According to researchers, the Phase III clinical trial of the DCVax-L cancer vaccine shows that it can expand the life of patients with both newly diagnosed and recurrent glioblastoma.
‘The nice thing about it is it’s non-toxic. Just like getting a vaccine for the flu or COVID that we are all familiar with,’ said Dr. Steven Toms, director of the Brain Tumor and Stereotactic Radiosurgery Program.”
Read the full article Here
Watch the full press conference Here
I could keep going, but the point is, you'll just state your not very relevant opinion again as if that counters reality and facts. It doesn't. But you'll do it anyway.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
